Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement | Zendy

Taku Inohara | Zendy; Pratik Manandhar | Zendy; Andrzej S. Kosinski | Zendy; Roland Matsouaka | Zendy; Shun Kohsaka | Zendy; Robert J. Mentz | Zendy; Vinod H. Thourani | Zendy; John D. Carroll | Zendy; Ajay J. Kirtane | Zendy; Joseph E. Bavaria | Zendy; David J. Cohen | Zendy; Todd L. Kiefer | Zendy; Jeffrey G. Gaca | Zendy; Samir Kapadia | Zendy; Eric D. Peterson | Zendy; Sreekanth Vemulapalli | Zendy

Open Access

Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement

Author(s) -

Taku Inohara,

Pratik Manandhar,

Andrzej S. Kosinski,

Roland Matsouaka,

Shun Kohsaka,

Robert J. Mentz,

Vinod H. Thourani,

John D. Carroll,

Ajay J. Kirtane,

Joseph E. Bavaria,

David J. Cohen,

Todd L. Kiefer,

Jeffrey G. Gaca,

Samir Kapadia,

Eric D. Peterson,

Sreekanth Vemulapalli

Publication year - 2018

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2018.18077

Subject(s) - medicine , ejection fraction , propensity score matching , heart failure , ace inhibitor , medical prescription , cardiology , valve replacement , retrospective cohort study , angiotensin converting enzyme , blood pressure , pharmacology , stenosis

Data are lacking on the effect of a renin-angiotensin system (RAS) inhibitor prescribed after transcatheter aortic valve replacement (TAVR). Treatment with a RAS inhibitor may reverse left ventricular remodeling and improve function.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research